

CLIA #: 31D2026917

Consulting Pathologist: Test Pathologist

PATIENT DEMOGRAPHICS

PATIENT INFORMATION:	PHYSICIAN INFORMATION:	SPECIMEN INFORMATION:
Patient, Test DOB: 1/1/1955 Gender/Age: M/64 SS#: UN:306872794	Test Physician Test Practice 300 Columbus Circle, Suite A, Edison NJ 08837 866.909.PATH, Fax:908-272-1478	ACCESSION #: TS22-01082 PROCEDURE DATE: 4/24/2022 DATE RECEIVED: 4/25/2022 REPORTED ON: 4/26/2022

CLINICAL HISTORY: Hematuria.

SPECIMEN RECEIVED: Voided urine, 90 cc of yellow clear fluid, in PreservCyt™

URINE CYTOLOGY DIAGNOSIS


SPECIMEN: SATISFACTORY FOR EVALUATION.
DIAGNOSIS: ATYPICAL, CANNOT RULE OUT UROTHELIAL CELL NEOPLASIA.

MICROSCOPIC FINDINGS:

- Single scattered urothelial cells, with mild to moderate atypia.
- Squamous cells, benign.
- Neutrophils.
- Erythrocytes.

COMMENTS:


- Suggest clinical correlation and follow up as appropriate..



UROVYSION™ FISH ANALYSIS

DIAGNOSIS: POSITIVE *
INTERPRETATION: POSITIVE FOR ANEUPLOIDY CEP GAIN OF 3, 7, 17.

Total Urothelial Cells Scored: 31	
Marker	Interpretation
CEP3	Positive
CEP7	Positive
CEP17	Positive
LSI 9p21	Negative



SUMMARY: A total of 31 cells analyzed, 6 cells showed a gain of 2 or more chromosomes (3,7,17).

***POSITIVE BY ANEUPLOIDY :** ≥4 cells with 3 or more signals of 2 or more CEP (3,7 or 17).

A negative urine cytology test does not rule out urothelial carcinoma. This test has a low sensitivity (50%) in detecting low-grade urothelial carcinoma. Am. J. Clin. Pathol. 2009;132:785-793.

UroVysion™ Testing: The performance of the UroVysion™ Assay (Abbott Molecular, Chicago, IL) for detection of urinary tract cancers has been approved by the Food and Drug Administration and is intended for use as a screen for genetic abnormalities in urothelial cells. This test is designed to detect aneuploidy for chromosomes 3,7,17 and homozygous deletion of the 9p21 locus via FISH. The UroVysion™ FISH assay test has not been approved for the utilization of bladder washings or upper urinary tract specimen. When utilized for these, the results should be interpreted in correlation with clinical history. The UroVysion™ assay was designed to detect genetic changes associated with most bladder cancers, there will be some bladder cancers whose genetic changes cannot be detected by the UroVysion™ assay. **Negative result does not rule out urothelial carcinoma.**

CPT	ICD-10
88112 88120 88313	R31.2 Date of Procedure: 4/24/2022

ELECTRONICALLY SIGNED OUT BY
Pathologist: <u>Test Pathologist</u> Test Pathologist